- Home
- ZIM vs MIRM Comparison
ZIM vs MIRM Comparison
Compare ZIM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIM
- MIRM
- Stock Information
- Founded
- ZIM 1945
- MIRM 2018
- Country
- ZIM Israel
- MIRM United States
- Employees
- ZIM N/A
- MIRM N/A
- Industry
- ZIM Marine Transportation
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ZIM Consumer Discretionary
- MIRM Health Care
- Exchange
- ZIM Nasdaq
- MIRM Nasdaq
- Market Cap
- ZIM 2.4B
- MIRM 1.9B
- IPO Year
- ZIM 2021
- MIRM 2019
- Fundamental
- Price
- ZIM $14.33
- MIRM $40.80
- Analyst Decision
- ZIM Sell
- MIRM Strong Buy
- Analyst Count
- ZIM 4
- MIRM 11
- Target Price
- ZIM $13.95
- MIRM $58.55
- AVG Volume (30 Days)
- ZIM 6.7M
- MIRM 432.9K
- Earning Date
- ZIM 05-20-2025
- MIRM 05-07-2025
- Dividend Yield
- ZIM 55.65%
- MIRM N/A
- EPS Growth
- ZIM N/A
- MIRM N/A
- EPS
- ZIM 17.82
- MIRM N/A
- Revenue
- ZIM $8,427,400,000.00
- MIRM $336,888,000.00
- Revenue This Year
- ZIM N/A
- MIRM $29.51
- Revenue Next Year
- ZIM N/A
- MIRM $20.27
- P/E Ratio
- ZIM $0.80
- MIRM N/A
- Revenue Growth
- ZIM 63.25
- MIRM 80.76
- 52 Week Low
- ZIM $11.04
- MIRM $23.83
- 52 Week High
- ZIM $30.15
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- ZIM 47.52
- MIRM 45.27
- Support Level
- ZIM $12.66
- MIRM $38.22
- Resistance Level
- ZIM $14.23
- MIRM $39.87
- Average True Range (ATR)
- ZIM 1.03
- MIRM 2.27
- MACD
- ZIM 0.28
- MIRM 0.23
- Stochastic Oscillator
- ZIM 88.68
- MIRM 61.83
About ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.